Note 11 - Subsequent Events	6 Months Ended
Jun. 30, 2025
Notes to Financial Statements
Subsequent Events [Text Block]	Note 11 – Subsequent Events Management has evaluated subsequent events through the date that the Company’s unaudited condensed consolidated financial statements were issued. Based on this evaluation, the Company has determined that no additional subsequent events have occurred, other than those noted below, which require disclosure through the date that these unaudited condensed consolidated financial statements were issued. On July 11, 2025, Alpha exercised its right under the Securities Purchase Agreement to purchase an additional 800 shares of Series F convertible into 671,818 shares of common stock, in the aggregate, at a conversion price of $1.1908 and warrants to purchase up to 671,818 shares of common stock at an exercise price of $1.1908 per share for an aggregate purchase price of $800,000. On July 14, 2025, an investor exercised Series A Warrants in a alternate cashless exercise and 63,017 shares of common stock were issued. On July 18, 2025, Alpha exercised its right under the Securities Purchase Agreement to purchase an additional 1,500 shares of Series F convertible into 1,071,429 shares of common stock, in the aggregate, at a conversion price of $1.40 and warrants to purchase up to 1,071,429 shares of common stock at an exercise price of $1.40 per share for an aggregate purchase price of $1,500,000. On July 23, 2025, Alpha exercised its right under the Securities Purchase Agreement to purchase an additional 1,000 shares of Series F convertible into 456,621 shares of common stock, in the aggregate, at a conversion price of $2.19 and warrants to purchase up to 456,621 shares of common stock at an exercise price of $2.19 per share for an aggregate purchase price of $1,000,000. The Company has issued a total of 2,680,704 shares of Common Stock for the conversion of 3,279 shares of Series F Preferred Stock with a stated value of $1,000 per share and conversion prices ranging from $0.82 - $1.40. During the month of July 2025, the Company received $6,526,485 related to the exercise of 7,868,924 Series B Warrants. As of July 31, 2025, there are 12,960 remaining Series B Warrants. On July 3, 2025, Alpha converted $8,612 of outstanding accrued interest into 10,383 shares of Common Stock at an average conversion rate of $0.8294. There was no remaining principle or accrued interest remaining on this convertible note payable after this conversion (see Note 5). On July 30, 2025 the Company filed a registration statement on Form S-3 (the "Resale Registration Statement") related to the resale of up to 7,700,000 shares of Common Stock that may be sold from time to time by Alpha (the "Selling Stockholder"). The 7,700,000 shares of Common Stock offered under this prospectus (the “Shares”) consist of (i) 456,621 shares of Common Stock underlying the Common Stock purchase warrant (an “Alpha Warrant”) at the exercise price of $2.19 per warrant share, issued and sold to the Selling Stockholder on July 23, 2025, in a private placement, (ii) 450,390 shares of Common Stock underlying an Alpha Warrant at the exercise price of $0.8294 per warrant share, issued and sold to the Selling Stockholder on February 7, 2025, in a private placement, (iii) 415,420 shares of Common Stock underlying an Alpha Warrant at the exercise price of $0.8294 per warrant share, issued and sold to the Selling Stockholder on March 17, 2025, in a private placement, (iv) 602,846 shares of Common Stock underlying an Alpha Warrant at the exercise price of $0.8294 per warrant share, issued and sold to the Selling Stockholder on May 5, 2025 in a private placement, (v) 418,831 shares of Common Stock underlying an Alpha Warrant at the exercise price of $1.1938 per warrant share, issued and sold to the Selling Stockholder on June 6, 2025, in a private placement, (vi) 838,364 shares of Common Stock underlying an Alpha Warrant at the exercise price of $1.1928 per warrant share, issued and sold to the Selling Stockholder on June 9, 2025, in a private placement, (vii) 797,067 shares of Common Stock underlying an Alpha Warrant at the exercise price of $1.2546 per warrant share, issued and sold to the Selling Stockholder on June 16, 2025, in a private placement, (viii) 357,143 shares of Common Stock underlying an Alpha Warrant at the exercise price of $1.400 per warrant share, issued and sold to the Selling Stockholder on July 18, 2025, in a private placement, and (ix) 714,286 shares of Common Stock underlying an Alpha Warrant at the exercise price of $1.400 per warrant share, issued and sold to the Selling Stockholder on July 18, 2025, in a private placement, 2,649,032 shares issuable upon conversion of Series F and exercise of the Alpha Warrants issued in connection with future exercises of the Selling Stockholder’s right to acquire additional shares of Series F and Alpha Warrants under the Series F Purchase Agreement. The Company is not selling any shares of its Common Stock under the Resale Registration Statement and will not receive any proceeds from the sale of any of the shares of Common Stock by the Selling Stockholder. The SEC declared the Resale Registration Statement effective on August 7, 2025. On August 8, 2025, as a result of the S-3, Alpha exercised their rights to convert 1,468,656 shares of Series F Warrants into 1,468,656 of Common Stock at an exercise price of $0.8294 for a gross proceeds of $1,218,103.

Note 11 - Subsequent Events

6 Months Ended

Jun. 30, 2025

Note 11 – Subsequent Events

Management has evaluated subsequent events through the date that the Company’s unaudited condensed consolidated financial statements were issued. Based on this evaluation, the Company has determined that no additional subsequent events have occurred, other than those noted below, which require disclosure through the date that these unaudited condensed consolidated financial statements were issued.

On July 11, 2025, Alpha exercised its right under the Securities Purchase Agreement to purchase an additional 800 shares of Series F convertible into 671,818 shares of common stock, in the aggregate, at a conversion price of $1.1908 and warrants to purchase up to 671,818 shares of common stock at an exercise price of $1.1908 per share for an aggregate purchase price of $800,000.

On July 14, 2025, an investor exercised Series A Warrants in a alternate cashless exercise and 63,017 shares of common stock were issued.

On July 18, 2025, Alpha exercised its right under the Securities Purchase Agreement to purchase an additional 1,500 shares of Series F convertible into 1,071,429 shares of common stock, in the aggregate, at a conversion price of $1.40 and warrants to purchase up to 1,071,429 shares of common stock at an exercise price of $1.40 per share for an aggregate purchase price of $1,500,000.

On July 23, 2025, Alpha exercised its right under the Securities Purchase Agreement to purchase an additional 1,000 shares of Series F convertible into 456,621 shares of common stock, in the aggregate, at a conversion price of $2.19 and warrants to purchase up to 456,621 shares of common stock at an exercise price of $2.19 per share for an aggregate purchase price of $1,000,000.

The Company has issued a total of 2,680,704 shares of Common Stock for the conversion of 3,279 shares of Series F Preferred Stock with a stated value of $1,000 per share and conversion prices ranging from $0.82 - $1.40.

During the month of July 2025, the Company received $6,526,485 related to the exercise of 7,868,924 Series B Warrants. As of July 31, 2025, there are 12,960 remaining Series B Warrants.

On July 3, 2025, Alpha converted $8,612 of outstanding accrued interest into 10,383 shares of Common Stock at an average conversion rate of $0.8294. There was no remaining principle or accrued interest remaining on this convertible note payable after this conversion (see Note 5).

On July 30, 2025 the Company filed a registration statement on Form S-3 (the "Resale Registration Statement") related to the resale of up to 7,700,000 shares of Common Stock that may be sold from time to time by Alpha (the "Selling Stockholder"). The 7,700,000 shares of Common Stock offered under this prospectus (the “Shares”) consist of (i) 456,621 shares of Common Stock underlying the Common Stock purchase warrant (an “Alpha Warrant”) at the exercise price of $2.19 per warrant share, issued and sold to the Selling Stockholder on July 23, 2025, in a private placement, (ii) 450,390 shares of Common Stock underlying an Alpha Warrant at the exercise price of $0.8294 per warrant share, issued and sold to the Selling Stockholder on February 7, 2025, in a private placement, (iii) 415,420 shares of Common Stock underlying an Alpha Warrant at the exercise price of $0.8294 per warrant share, issued and sold to the Selling Stockholder on March 17, 2025, in a private placement, (iv) 602,846 shares of Common Stock underlying an Alpha Warrant at the exercise price of $0.8294 per warrant share, issued and sold to the Selling Stockholder on May 5, 2025 in a private placement, (v) 418,831 shares of Common Stock underlying an Alpha Warrant at the exercise price of $1.1938 per warrant share, issued and sold to the Selling Stockholder on June 6, 2025, in a private placement, (vi) 838,364 shares of Common Stock underlying an Alpha Warrant at the exercise price of $1.1928 per warrant share, issued and sold to the Selling Stockholder on June 9, 2025, in a private placement, (vii) 797,067 shares of Common Stock underlying an Alpha Warrant at the exercise price of $1.2546 per warrant share, issued and sold to the Selling Stockholder on June 16, 2025, in a private placement, (viii) 357,143 shares of Common Stock underlying an Alpha Warrant at the exercise price of $1.400 per warrant share, issued and sold to the Selling Stockholder on July 18, 2025, in a private placement, and (ix) 714,286 shares of Common Stock underlying an Alpha Warrant at the exercise price of $1.400 per warrant share, issued and sold to the Selling Stockholder on July 18, 2025, in a private placement, 2,649,032 shares issuable upon conversion of Series F and exercise of the Alpha Warrants issued in connection with future exercises of the Selling Stockholder’s right to acquire additional shares of Series F and Alpha Warrants under the Series F Purchase Agreement. The Company is not selling any shares of its Common Stock under the Resale Registration Statement and will not receive any proceeds from the sale of any of the shares of Common Stock by the Selling Stockholder. The SEC declared the Resale Registration Statement effective on August 7, 2025.

On August 8, 2025, as a result of the S-3, Alpha exercised their rights to convert 1,468,656 shares of Series F Warrants into 1,468,656 of Common Stock at an exercise price of $0.8294 for a gross proceeds of $1,218,103.